ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Brain Diseases
Nervous System Diseases
Neurocognitive Disorders

Alzheimer's Disease trials near Birmingham, AL, USA:

DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU...

Enrolling
Alzheimer's Disease
Alzheimer's Disease, Familial
Drug: lecanemab

Phase 3

The Washington University
The Washington University

Birmingham, Alabama, United States and 5 other locations

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo
Drug: CT1812

Phase 2

Cognition Therapeutics
Cognition Therapeutics

Birmingham, Alabama, United States and 50 other locations

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Active, not recruiting
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Lecanemab
Drug: Matching Placebo (E2814)

Phase 2, Phase 3

The Washington University
The Washington University

Birmingham, Alabama, United States and 37 other locations

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Solanezumab
Drug: E2814

Phase 2, Phase 3

The Washington University
The Washington University

Birmingham, Alabama, United States and 37 other locations

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Active, not recruiting
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Birmingham, Alabama, United States and 109 other locations

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (DIAN-TU-002)

compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD).Stage 2 will evaluate the effect of earl...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Matching Placebo (Remternetug)
Drug: Remternetug

Phase 2, Phase 3

The Washington University
The Washington University

Birmingham, Alabama, United States and 34 other locations

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (DIAN-TU)

investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determ...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Matching Placebo (Remternetug)
Drug: Remternetug (SC)

Phase 2, Phase 3

The Washington University
The Washington University

Birmingham, Alabama, United States and 34 other locations

Locations recently updated

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

outpatient study in subjects with psychosis associated with Alzheimer's Disease.The primary objective of the study is to evaluate r ...

Enrolling
Psychosis Associated With Alzheimer's Disease
Drug: Placebo
Drug: KarXT

Phase 3

Karuna Therapeutics
Karuna Therapeutics

Homewood, Alabama, United States and 119 other locations

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's...

Enrolling
Alzheimer Disease
Agitation
Drug: Placebo
Drug: BMS-986368

Phase 2

Celgene
Celgene

Homewood, Alabama, United States and 45 other locations

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease...

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

Phase 3

Lilly
Lilly

Homewood, Alabama, United States and 221 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems